STOCK TITAN
  1. Home
  2. Sec-filings
  3. CERO
  4. [Form 4] CERO THERAPEUTICS HOLDINGS, INC. Insider Trading Activity

CERO Therapeutics (CERO) director receives stock options for 1.82M shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CERO Therapeutics Holdings director Francois Eric received a stock option grant as equity compensation. The award covers options to buy 1,823,278 shares of Common Stock at an exercise price of $0.055 per share, held directly.

The options vest in full on the earlier of August 13, 2026 or the achievement of a specified clinical milestone in 2026, provided Eric remains in continuous service through the vesting date. The options expire on March 3, 2036, and following this grant he holds options for 1,823,278 underlying shares.

Positive

  • None.

Negative

  • None.
Insider Francois Eric
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 1,823,278 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 1,823,278 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 1,823,278 shares Stock Option (Right to Buy) covering Common Stock
Exercise price $0.055 per share Stock option strike price for the grant
Shares after transaction 1,823,278 shares Total options held following the grant
Vesting date August 13, 2026 Vests earlier of this date or a 2026 clinical milestone
Expiration date March 3, 2036 Option expiration for the 1,823,278-share award
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
vesting financial
"The shares underlying this option shall vest in full on the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
clinical milestone medical
"the achievement of a specified clinical milestone in 2026"
continuous service financial
"subject to the reporting person's continuous service through the applicable vesting date"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Francois Eric
(Last)(First)(Middle)
CERO THERAPEUTICS HOLDINGS, INC.
201 HASKINS WAY, SUITE 230
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CERO THERAPEUTICS HOLDINGS, INC. [ CERO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.05503/04/2026A1,823,278 (1)03/03/2036Common Stock1,823,278$0.001,823,278D
Explanation of Responses:
1. The shares underlying this option shall vest in full on the earlier of (i) August 13, 2026 or (ii) the achievement of a specified clinical milestone in 2026, in each case subject to the reporting person's continuous service through the applicable vesting date.
/s/ Andrew Kucharchuk, Attorney-in-Fact04/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CERO (CERO) report in this Form 4?

CERO reported a stock option grant to director Francois Eric. He received options over 1,823,278 Common Stock shares as equity compensation, rather than buying shares in the open market, reflecting a non-cash award tied to future vesting conditions.

How many CERO shares are covered by Francois Eric’s new stock options?

The grant covers options on 1,823,278 shares of CERO Common Stock. This entire amount was awarded in a single transaction and represents Eric’s reported post-transaction option holdings linked to this grant in the filing.

What is the exercise price of Francois Eric’s CERO stock option grant?

The options have an exercise price of $0.055 per share. This price is the amount Eric would pay per share to convert the stock options into CERO Common Stock if he exercises the award after vesting.

When do Francois Eric’s CERO stock options vest?

The options vest in full on the earlier of August 13, 2026 or upon achievement of a specified clinical milestone in 2026. Vesting is conditional on Eric’s continuous service through whichever vesting event occurs first.

What is the expiration date of the CERO stock options granted to Francois Eric?

The options expire on March 3, 2036. After this date, any unexercised portion of the 1,823,278-share grant will lapse, meaning Eric would no longer be able to purchase CERO shares under this award.

Is Francois Eric’s CERO Form 4 transaction an open-market purchase or sale?

It is not an open-market trade. The Form 4 reports a stock option grant coded as a grant or award acquisition, meaning CERO awarded options to Eric as compensation rather than him buying or selling shares on the market.